Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Phathom Pharmaceuticals reported a quarterly loss of $0.15 per share, outperforming the Zacks Consensus Estimate of a loss of $0.30, and showing improvement from a loss of $1.32 per share a year ago, resulting in an earnings surprise of +50.00% [1] - The company achieved revenues of $49.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.64% and significantly up from $16.35 million in the same quarter last year [2] - Phathom Pharmaceuticals' stock has increased by approximately 66.6% since the beginning of the year, compared to a 17.2% gain in the S&P 500 [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $55.35 million, and for the current fiscal year, it is -$2.31 on revenues of $172.56 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Phathom Pharmaceuticals belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]